Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) to participate at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference
  • This conference is set to be presented by Maxim Group and hosed by M-Vest taking place September 22, 2021
  • The discussion will focus on the topics surrounding Deliver, Manufacturing, & Technology
  • Its pre-clinical study involving psilocybin and NAC (N-Acetylcysteine) stands to progress
  • Lobe Sciences Ltd. (LOBE) is in the grey and is trading at C$0.05 at 12:24 pm ET 

Lobe Sciences (LOBE) CEO Philip Young will participate in a round table discussion at the Advances in Mental Health Psychedelics and Non-Psychedelics Conference.

This conference is set to be presented by Maxim Group and hosed by M-Vest taking place September 22, 2021.

The discussion will focus on the topics surrounding Deliver, Manufacturing, & Technology and “What does it take to succeed in Psychedelics beyond drugs and clinics”, beginning at 3:00 pm ET on Wednesday, September 22, 2021.

On September 3, Loe released a corporate update to its shareholders highlighting some key points.

Its pre-clinical study involving psilocybin and NAC (N-Acetylcysteine) led by Principal Investigator, Dr. Michael Hoffer of the University of Miami stands to progress and the company is in the process of analyzing the data.

Lobe also continues to strengthen its overall product, device and intellectual property portfolio through acquisitions and our development efforts. Other key highlights include: On February 18, 2021, the successful completion and testing of the proof of concept prototype of its proprietary nasal mist device.

Lastly, on April 27, 2021, Lobe entered into a joint venture agreement with Virtual Psychedelics Incorporated to design, develop and commercialize the Krysalis Pod, a state-of-the-art media device that will deliver immersive virtual experiences without a headset.

Lobe Sciences is a life sciences company focused on psychedelic medicines.

Through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

Lobe Sciences Ltd. (LOBE) is in the grey and is trading at C$0.05 at 12:24 pm ET. 

More From The Market Herald
Small Pharma - CEO, Peter Rands.

" Small Pharma (TSXV:DMT) granted European patent

Small Pharma (DMT) has been granted a European patent, strengthening its ketamine-based patent portfolio.

" Levitee Labs (CSE:LVT) enters into credit facility for up to $12 Million

Levitee Labs Inc. (LVT) has entered into a financing agreement for up to $12 million to fund further business expansion.
Small Pharma - Chief Medical and Scientific Officer, Carol Routledge.

" Small Pharma (TSXV:DMT) granted fast-track designation for DMT-assisted therapy

Small Pharma (DMT) has been granted fast-track designation in the U.K. for DMT-assisted therapy for major depressive disorder.

" Psyched Wellness (CSE:PSYC) shares preliminary data from amanita muscaria mushroom study

Psyched Wellness Ltd. (PSYC) has released its preliminary data revealing a potential new functional property and health benefit of AME-1.